pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·2h ago·1 min read
save

Commure ends referral payment program for its AI clinic tools

Aug 13, 2026·read at STAT ↗Neutral

Commure, a health-software firm valued at about $7 billion, announced it is ending the referral-payment arrangements it had with partners who promoted its artificial-intelligence products to medical clinics.

The decision was communicated via internal emails from chief legal officer Dan Brian, giving partners a 30-day notice that the agreements would cease. Any amounts owed up to the termination date will be paid in full.

The move follows a STAT investigation that highlighted the company’s practice of offering thousands of dollars to customers and other parties for referrals to its AI tools.

Commure did not provide a detailed rationale for the change, but the termination of the program could affect how the company acquires new clinic customers going forward.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “STAT+: Commure terminates payments under its customer referral programs tied to AI products”

read at STAT ↗
562 words · retrieved 2h ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
NEUROCRINENEUROCRINE BIOSCIENCES INCSanofiUltragenyx Pharmaceutical Inc.
drugs
Rare Disease
topics
Drug ShortageRare Disease

related stories

  • 1d agoSTAT+: Pharmalittle: We’re reading about Lilly ‘black market’ lawsuits, pushback over Trump vaccine plan, and moreSTAT
  • 9h agoSTAT+: Eli Lilly targets booming black market for retatrutideSTAT
  • 13h agoSTAT+: Neurocrine Biosciences and the delicate balance of benefit and riskSTAT
  • 1d agoDeaths reported after treatment with Neurocrine’s approved Prader-Willi drugBioSpace
  • 1d agoSTAT+: Definium Therapeutics says its LSD therapy eased anxiety in late-stage trialSTAT